New Series: Biotechnology Companies at Forefront of Global Health Innovation – Post #1: GlaxoSmithKline & Alnylam Pharmaceuticals
On July 8 2009, GlaxoSmithKline (GSK) and Alnylam Pharmaceuticals, Inc. announced a patent pool to compile intellectual property (IP) to develop treatments for 16 tropical diseases as identified by the FDA including malaria, TB and Chagas, found in 49 Least Developed Countries as defined by the United Nations. (GSK press release)
The pool currently has two members (GSK and Alnylam) but is inviting others to participate. The donated IP will be non-exclusively licensed and royalty free for the purpose of addressing the above mentioned unmet needs. The current members of the patent pool will also provide for know-how, technical resources and training to be available to those who access the pool. The pool will also help in accessing financing where possible.
GSK has donated IP for some of its New Chemical Entities (NCEs) and Alnylam has donated its RNAi platform technology to the pool for limited field of use.
For more information you can visit Alnylam and GSK websites. We will have updates as they become available.